Disufenton sodium

製品コードS6002 バッチS600202

印刷

化学情報

Chemical Structure Synonyms NXY-059, Cerovive Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C11H13NNa2O7S2
分子量 381.33 CAS No. 168021-79-2
Solubility (25°C)* 体外 DMSO 76 mg/mL (199.3 mM)
Water 76 mg/mL (199.3 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Disufenton Sodium (NXY-059, Cerovive) is a novel nitrone, shows efficacious neuroprotective effects. Phase 3.
in vitro

NXY-059 is more soluble than the spin trapping agent α-phenyl-N-tert-butyl nitrone (PBN). [1] In an in vitro blood-brain barrier (BBB) model, 250 mM of NXY-059 administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by NXY-059. [2]
in vivo

NXY-059 reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion in a dose-dependent manner. At equimolar doses (3.0 mg/kg for NXY-059 and 1.4 mg/kg for PBN), NXY-059 is more efficacious than PBN. Similar results are obtained when a recovery period of 7 days is allowed. The window of therapeutic opportunity for NXY-059 is 3 to 6 hours after the start of recirculation. [1] NXY-059, a free radical-trapping agent, has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. NXY-059 treatment reduces the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter. [3] Treatment with NXY-059 (50 mg/kg subcutaneous plus 8.8 mg/kg/h for 3 days subcutaneous delivered via implanted osmotic pumps) significantly decreases neurological impairment following intracerebral hemorrhage in rat, and reduces the neutrophil infiltrate observed 48 hours post-hemorrhage in the vicinity of the hematoma, and the number of TUNEL-positive cells 48 hours post-hemorrhage at the hematoma margin. [4]

プロトコル(参考用のみ)

動物実験 動物モデル Monofilament fishing line is used to produce occlusion and neurologic deficit in male Wistar rats
投薬量 0.3, 3.0 or 30 mg/kg
投与方法 Administered into the right jugular vein.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

A comprehensive evaluation of catalase-like activity of different classes of redox-active therapeutics [Tovmasyan A, et al. Free Radic Biol Med, 2015, 86:308-21] PubMed: 26026699

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。